166 related articles for article (PubMed ID: 25430444)
1. Correlation between molecular biomarkers and risk factors for the clinical progression of benign prostatic hyperplasia using tissue microarray immunostaining.
Ma D; Yang B; Zhou Z; Pan D; Zhang X
Chin Med J (Engl); 2014; 127(23):4031-5. PubMed ID: 25430444
[TBL] [Abstract][Full Text] [Related]
2. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia.
Shariat SF; Ashfaq R; Roehrborn CG; Slawin KM; Lotan Y
J Urol; 2005 Nov; 174(5):2046-50. PubMed ID: 16217391
[TBL] [Abstract][Full Text] [Related]
3. The angiogenic switch for vascular endothelial growth factor-A and cyclooxygenase-2 in prostate carcinoma: correlation with microvessel density, androgen receptor content and Gleason grade.
Gyftopoulos K; Vourda K; Sakellaropoulos G; Perimenis P; Athanasopoulos A; Papadaki E
Urol Int; 2011; 87(4):464-9. PubMed ID: 21912077
[TBL] [Abstract][Full Text] [Related]
4. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
[TBL] [Abstract][Full Text] [Related]
5. [Expressions of SIgA and alpha 1-AR in benign prostatic hyperplasia combined with chronic prostatitis and their implications].
Gao WJ; Wang YM; Wang CH; Yang XK; Wan L; Li WP
Zhonghua Nan Ke Xue; 2013 Apr; 19(4):315-20. PubMed ID: 23678709
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: association with asymptomatic inflammatory prostatitis NIH category IV.
Engelhardt PF; Seklehner S; Brustmann H; Lusuardi L; Riedl CR
Scand J Urol; 2015 Apr; 49(2):120-6. PubMed ID: 25363611
[TBL] [Abstract][Full Text] [Related]
7. [Expression and significance of PCNA and p27 in benign prostate hypertrophy and prostate carcinoma].
Lai JS; Xia Q; Zhang XB; Zhao GP; Xu SL; Zheng DS
Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):476-8. PubMed ID: 15555337
[TBL] [Abstract][Full Text] [Related]
8. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
9. Impact of primary hypertension on hematuria of the patients with benign prostatic hyperplasia.
Guo LJ; Tang Y; Guo CM; Zhang XH
Chin Med J (Engl); 2010 May; 123(9):1154-7. PubMed ID: 20529555
[TBL] [Abstract][Full Text] [Related]
10. Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.
Nicholson TM; Sehgal PD; Drew SA; Huang W; Ricke WA
Differentiation; 2013; 85(4-5):140-9. PubMed ID: 23792768
[TBL] [Abstract][Full Text] [Related]
11. [Correlation of histological prostatitis with PSA, prostate volume, PSAD, IPSS, Qmax and PVR in BPH patients].
Zhang HT; Xu Y; Chang JW; Zhang ZH; Liu RL; Ma BJ
Zhonghua Nan Ke Xue; 2012 Mar; 18(3):208-11. PubMed ID: 22474983
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia.
Jackson MW; Bentel JM; Tilley WD
J Urol; 1997 Jun; 157(6):2323-8. PubMed ID: 9146664
[TBL] [Abstract][Full Text] [Related]
13. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
14. [Correlation of serum prostate specific antigen, the volume and the intravesical prostatic protrusion for diagnosing bladder outlet obstruction in patients with benign prostate hyperplasia].
Bantis A; Zissimopoulos A; Kalaytzis C; Giannakopoulos S; Sountoulides P; Agelonidou E; Voudalikakis C; Touloupidis S
Hell J Nucl Med; 2007; 10(2):138-43. PubMed ID: 17684595
[TBL] [Abstract][Full Text] [Related]
15. [Histological changes of the prostate and acute urinary retention in patients with benign prostatic hyperplasia].
Bao QB; He GH; Liu GY; Zhang CG; Yang C
Zhonghua Nan Ke Xue; 2013 Sep; 19(9):811-4. PubMed ID: 24386860
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid.
Sakamoto S; Yokoyama M; Zhang X; Prakash K; Nagao K; Hatanaka T; Getzenberg RH; Kakehi Y
Endocrinology; 2004 Jun; 145(6):2929-40. PubMed ID: 14988385
[TBL] [Abstract][Full Text] [Related]
17. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
Soulitzis N; Karyotis I; Delakas D; Spandidos DA
Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
[TBL] [Abstract][Full Text] [Related]
18. [Histological characteristics of the prostate in men who receive re-TURP for benign prostatic hyperplasia and their clinical significance].
Sun QZ; Guan TY; Qi JG; Cao JY; Wu G; Yang N; Cheng ZY; Liang J; Wang Q
Zhonghua Nan Ke Xue; 2010 Feb; 16(2):118-22. PubMed ID: 20369693
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate.
Ravindranath N; Wion D; Brachet P; Djakiew D
J Androl; 2001; 22(3):432-43. PubMed ID: 11330643
[TBL] [Abstract][Full Text] [Related]
20. [Correlation of benign prostatic hyperplasia with hyperlipemia].
Li PJ; Zhang XH; Guo LJ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):387-9. PubMed ID: 15854349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
